All Stories

  1. Psychiatric health of Icelandic adults 40 years or older: A nationwide study of diagnoses, medications, and symptoms
  2. Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study
  3. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study
  4. Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS
  5. Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing
  6. Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
  7. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study
  8. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
  9. Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program
  10. Prevalence and Predictors of Achieving Sustained Remission in Psoriatic Arthritis: A Swedish Nationwide Registry Study
  11. Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study
  12. Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study
  13. Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population‐based screening study
  14. The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
  15. Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study
  16. Depressive symptom trajectories among general population during the COVID-19 pandemic in Iceland: a prospective cohort study (2020–2023)
  17. Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia
  18. Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
  19. Deciphering the genetics and mechanisms of predisposition to multiple myeloma
  20. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
  21. Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
  22. Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry
  23. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
  24. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
  25. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
  26. Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden
  27. Trends of perceived disruption in healthcare services during the pandemic: findings from the COVID-19 National Resilience Cohort in Iceland
  28. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
  29. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
  30. Long COVID in Icelandic Children: A Matched Cohort Study of Nonspecific Symptoms Following SARS-CoV-2 Infection
  31. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
  32. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
  33. Physical and cognitive impact following SARS-CoV-2 infection in a large population-based case-control study
  34. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
  35. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
  36. Prevalence of smoldering multiple myeloma based on nationwide screening
  37. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
  38. Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
  39. Comment on: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen: reply
  40. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
  41. SARS-CoV-2 Infections in Icelandic Children: Close Follow-up of All Confirmed Cases in a Nationwide Study
  42. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
  43. Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance
  44. Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen
  45. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program—A Prospective Nationwide, Population-Based Study
  46. Symptoms, physical measures and cognitive tests after SARS-CoV-2 infection in a large population-based case-control study
  47. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting
  48. The first wave of COVID‐19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric well‐being
  49. A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
  50. Does biologic therapy impact the development of PsA among patients with psoriasis?
  51. Validity of chronic disease diagnoses in Icelandic healthcare registries
  52. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
  53. Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors: A Nationwide Retrospective Cohort Study
  54. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study
  55. Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies
  56. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study
  57. No One Will be Safe Until Our Children are Safe: Parent’s Attitude Towards COVID-19 Childhood Immunization
  58. Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population
  59. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
  60. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
  61. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
  62. Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting
  63. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study
  64. Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance
  65. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
  66. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study
  67. FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
  68. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
  69. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
  70. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
  71. Golimumab in the treatment of psoriatic arthritis
  72. Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents
  73. Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review
  74. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
  75. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis
  76. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study
  77. Treatment as Prevention for Hepatitis C (TraP HepC). A Real-world Experience from the First 12 Months of a Nationwide Elimination Program in Iceland
  78. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries
  79. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis
  80. Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study
  81. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
  82. Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group
  83. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
  84. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network
  85. Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis
  86. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study
  87. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study
  88. Prevalence and treatment patterns of psoriatic arthritis in the UK
  89. Psoriatic Arthritis and Onycholysis — Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study
  90. Obesity and the risk of psoriatic arthritis: a population-based study
  91. Re: Risk of malignancy associated with Lyme disease: Still up in the air
  92. Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden
  93. Prevalence of the Metabolic Syndrome in Psoriasis
  94. Validation of Psoriatic Arthritis Diagnoses in Electronic Medical Records Using Natural Language Processing
  95. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
  96. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study
  97. A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study
  98. A ‘pilot’ study on air-travel and venous thromboembolism
  99. The relationship between cancer and rheumatoid arthritis: still a large research agenda
  100. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells